TY - JOUR
T1 - Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004-2022
AU - Graier, Thomas
AU - Salmhofer, Wolfgang
AU - Jonak, Constanze
AU - Weger, Wolfgang
AU - Zikeli, Claudia
AU - Gruber, Barbara
AU - Sator, Paul
AU - Prillinger, Knut
AU - Mlynek, Alexander
AU - Schütz-Bergmayr, Martina
AU - Richter, Leo
AU - Ratzinger, Gudrun
AU - Sassmann, Christoph
AU - Painsi, Clemens
AU - Häring, Nina
AU - Wippel-Slupetzky, Katharina
AU - Skvara, Hans
AU - Trattner, Hannes
AU - Inzinger, Martin
AU - Bangert, Christina
AU - Ellersdorfer, Christina
AU - Falkensteiner, Katharina
AU - Sadoghi, Birgit
AU - Gruber-Wackernagel, Alexandra
AU - Hofer, Angelika
AU - Legat, Franz
AU - Lange-Asschenfeldt, Bernhard
AU - Schmuth, Matthias
AU - Vujic, Igor
AU - Hötzenecker, Wolfram
AU - Saxinger, Werner
AU - Müllegger, Robert
AU - Quehenberger, Franz
AU - Wolf, Peter
N1 - Publisher Copyright:
© 2023 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
PY - 2023/12
Y1 - 2023/12
N2 - Background and Objectives: This study analyzed the extent to which the recent introduction of more effective treatments has led to an improvement in real-world psoriasis patients. Patients and Methods: Patient characteristics and the first-year treatment effectiveness in biologic-naive patients have been analyzed since 2004 until now, irrespective of treatment switches. Results: Data from 2,729 patients were eligible for this analysis. The proportion of female patients increased significantly over the years from 29.9% to 36.2% (p < 0.028), while the number of patients with psoriatic arthritis declined from 36.6% to 30.0% (p < 0.001). Moreover, the duration of psoriatic disease and PASI at the start of the treatment significantly decreased. Last observation carrief forward (LOCF) analysis indicated that PASI 90 response increased from 18.9 to 44.6% at 3 months and from 32.9 to 66.8% at 12 months after treatment started. Similary, the PASI ≤ 3 rates increased from 33.2% to 66.0% at 3 months and from 41.9% to 78.9% at 12 months after the treatment started. Conclusions: The continuous introduction of more efficient biologics has led to significant improvements in patient care and clinical outcomes. Though one out of three to five patients, depending on the endpoint selected, nowadays still does not achieve an entirely satisfactory treatment response (i.e., PASI 90 or PASI ≤ 3).
AB - Background and Objectives: This study analyzed the extent to which the recent introduction of more effective treatments has led to an improvement in real-world psoriasis patients. Patients and Methods: Patient characteristics and the first-year treatment effectiveness in biologic-naive patients have been analyzed since 2004 until now, irrespective of treatment switches. Results: Data from 2,729 patients were eligible for this analysis. The proportion of female patients increased significantly over the years from 29.9% to 36.2% (p < 0.028), while the number of patients with psoriatic arthritis declined from 36.6% to 30.0% (p < 0.001). Moreover, the duration of psoriatic disease and PASI at the start of the treatment significantly decreased. Last observation carrief forward (LOCF) analysis indicated that PASI 90 response increased from 18.9 to 44.6% at 3 months and from 32.9 to 66.8% at 12 months after treatment started. Similary, the PASI ≤ 3 rates increased from 33.2% to 66.0% at 3 months and from 41.9% to 78.9% at 12 months after the treatment started. Conclusions: The continuous introduction of more efficient biologics has led to significant improvements in patient care and clinical outcomes. Though one out of three to five patients, depending on the endpoint selected, nowadays still does not achieve an entirely satisfactory treatment response (i.e., PASI 90 or PASI ≤ 3).
KW - Psoriasis
KW - biologics
KW - psoriasis treatment
KW - psoriatic arthritis
UR - http://www.scopus.com/inward/record.url?scp=85175419055&partnerID=8YFLogxK
U2 - 10.1111/ddg.15213
DO - 10.1111/ddg.15213
M3 - Journal article
C2 - 37907427
SN - 1610-0379
VL - 21
SP - 1513
EP - 1523
JO - JDDG - Journal of the German Society of Dermatology
JF - JDDG - Journal of the German Society of Dermatology
IS - 12
ER -